OncBioMune Selects Theradex as CRO for Two Phase 2 Trials of ProscaVax for Prostate Cancer
March 08, 2018 09:15 ET
|
OncBioMune, L.L.C.
BATON ROUGE, La., March 08, 2018 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the...
OncBioMune Submits Phase 2 Protocol to Urology Centers of North Texas
February 28, 2018 08:29 ET
|
OncBioMune, L.L.C.
BATON ROUGE, La., Feb. 28, 2018 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the...
OncBioMune Provides Updates on two Phase 2 Clinical Trials of ProscaVax for Prostate Cancer
February 26, 2018 12:47 ET
|
OncBioMune, L.L.C.
BATON ROUGE, La., Feb. 26, 2018 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the...
OncBioMune Provides Update on Market Activity
February 16, 2018 16:23 ET
|
OncBioMune, L.L.C.
BATON ROUGE, La., Feb. 16, 2018 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the...
OncBioMune Signs Letter of Intent to Initiate Phase 2 Trial of ProscaVax for Advanced Prostate Cancer with Urology Clinics of North Texas
February 05, 2018 08:45 ET
|
OncBioMune, L.L.C.
BATON ROUGE, La., Feb. 05, 2018 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the...
70% of Advanced Prostate Cancer Patients Treated with ProscaVax Demonstrate Improvement in PSA Doubling Time
January 10, 2018 09:20 ET
|
OncBioMune, L.L.C.
BATON ROUGE, La., Jan. 10, 2018 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the...
One-Year Follow-Up Shows 71.4% Progression-Free Survival in 14 Prostate Cancer Patients Treated with ProscaVax in Phase 1 Clinical Trial
December 21, 2017 11:26 ET
|
OncBioMune, L.L.C.
BATON ROUGE, La., Dec. 21, 2017 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged in the...
100% of Prostate Cancer Patients Completing 31-Week Post-Therapy Exam After Treatment with OncBioMune Immunotherapy Show No Disease Progression
December 05, 2017 08:29 ET
|
OncBioMune, L.L.C.
BATON ROUGE, La., Dec. 05, 2017 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged in the...
80% of Prostate Cancer Patients in OncBioMune Phase 1 Clinical Trial of ProscaVax Show No Disease Progression at the First Post-Therapy Follow-up
November 13, 2017 08:25 ET
|
OncBioMune, L.L.C.
BATON ROUGE, La., Nov. 13, 2017 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged in the...
OncBioMune Preparing to Initiate Trials of Novel Therapeutic Ovarian Cancer Vaccine
October 17, 2017 09:07 ET
|
OncBioMune, L.L.C.
BATON ROUGE, La., Oct. 17, 2017 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged in the...